Vera Therapeutics is a clinical-stage biotechnology company with all investment value dependent on the atacicept pipeline, having missed earnings in all four recent quarters and burning cash at a negative free cash flow level, while analysts project 128% upside — a high-risk, binary-outcome situation requiring a quality improvement catalyst to justify holding.
Thesis pillars
- Atacicept Pipeline Binary Risk→Stable
- Cash Burn Fcf Negative Quality→Stable
- High Short Interest Momentum Recovery→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 26, 2026
Vera Therapeutics, Inc. (VERA) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $30.94: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 7.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 21%; Below-average business quality; Below long-term trend.
Vera Therapeutics is a late clinical-stage biotech with no approved products, focused on atacicept, a BAFF/APRIL inhibitor in a BLA for IgAN with a July 7, 2026 PDUFA date after Phase 3 ORIGIN 3 met its primary endpoint. The company held $714.6 million in cash as of December 31,... Read more
Sell if holding. Engine safety override at $30.94: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 7.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 21%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 54. Score 5.2/10, moderate confidence.
Passes 6/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 7d<=7d. Suitability: speculative.
About Vera Therapeutics, Inc.
About Vera Therapeutics, Inc.
Vera Therapeutics' lead asset atacicept received FDA Priority Review in January 2026 with a PDUFA target action date of July 7, 2026 for IgAN, after the pivotal Phase 3 ORIGIN 3 trial met its primary efficacy endpoint in June 2025 with a 46% reduction in UPCR from baseline and a statistically significant 42% reduction versus placebo (p<0.0001). The company held $714.6 million in cash and marketable securities as of December 31, 2025, and incurred net losses of $299.6 million for fiscal year 2025, with an accumulated deficit of $760.9 million as of that date.
Vera generates no product revenue and funds operations through equity issuances and debt. In June 2025, the company entered a Loan and Security Agreement with Oxford Finance LLC providing up to $500 million in borrowing capacity, with $75 million outstanding as of December 31, 2025. Atacicept is a native human TACI-Fc fusion protein that inhibits both BAFF and APRIL, the cytokines that drive B-cell production of the autoantigen Gd-IgA1 in IgAN, dosed once weekly via subcutaneous injection for at-home administration. The IgAN treatment landscape includes five approved agents: budesonide reformulated as TARPEYO and KINPEYGO (Asahi Kasei), sparsentan as FILSPARI (Travere Therapeutics), iptacopan as FABHALTA (Novartis), sibeprenlimab as VOYXACT (Otsuka), and atrasentan as VANRAFIA (Novartis). Beyond IgAN, atacicept is being evaluated in membranous nephropathy, FSGS, and other autoimmune kidney diseases via the Phase 2 PIONEER trial; a preclinical BAFF/APRIL inhibitor VT-109 was acquired from Stanford in January 2025.
Show full overview
The July 7, 2026 PDUFA date concentrates near-term company value in a single FDA action under the Accelerated Approval Program; the ORIGIN 3 key secondary endpoint—eGFR stabilization at 104 weeks—is expected to support full approval with results estimated in 2027. Prior atacicept trials in systemic lupus erythematosus missed the primary endpoint in the overall study population, a precedent the 10-K explicitly discloses as context for binary approval risk. The company will require substantial additional funding beyond current cash reserves to support commercialization if atacicept is approved, and the 2025 Loan Agreement with Oxford Finance could restrict operating flexibility if covenants are breached.
See also: Healthcare · Biotechnology
From Vera Therapeutics, Inc.'s most recent 10-K filing, extracted June 16, 2026.
Recent developments
updated 2026-10-29Recent Developments — Vera Therapeutics, Inc.
Latest news
- NEWS Vera Therapeutics Announces Its ORIGIN 3 Study Of TRUTAKNA In Adults With Primary IgA Nephropathy Achieves Primary Endpo — benzinga Oct 22, 2026 positive
- NEWS Vera Therapeutics Announces Upcoming Investor Webcasts for ASN Kidney Week and Q3 2026 Financial Results — fiscal.ai Oct 20, 2026 neutral
- NEWS Leerink Partners Initiates Coverage On Vera Therapeutics with Market Perform Rating, Announces Price Target of $34 — benzinga Oct 12, 2026
- NEWS Alignment Healthcare, RenX Enterprises And Other Big Stocks Moving Lower In Friday’s Pre-Market Session — benzinga Oct 9, 2026 neutral
- NEWS Vera Therapeutics To Present Multiple Presentations At American Society Of Nephrology Kidney Week 2026 For Its Final Eff — benzinga Oct 2, 2026 positive
Generated 2026-10-29T11:14:36Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineatacicept10-K Item 1: 'Our lead product candidate, atacicept, is currently being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·2 ceiling hits
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $30.94: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 7.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 21%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 54. Prior stop was $28.77. Score 5.2/10, moderate confidence.
Analyst target: $66.78 (+115.8% upside). Prior stop was $28.77. Stop-loss: $28.77.
Concentration risk — Pipeline: atacicept; Quality below floor (1.6 < 4.0); Value-trap signals (4/5): Margin compression (op margin -81.6%), High leverage (D/E 1.7), Material insider selling (4 sells, 0.03% of cap)….
Vera Therapeutics, Inc. trades at a P/E of N/A (forward -7.3). TrendMatrix value score: 9.0/10. Verdict: Sell.
20 analysts cover VERA with a consensus score of 4.3/5. Average price target: $74.
What does Vera Therapeutics, Inc. do?Vera Therapeutics is a late clinical-stage biotech with no approved products, focused on atacicept, a BAFF/APRIL...
Vera Therapeutics is a late clinical-stage biotech with no approved products, focused on atacicept, a BAFF/APRIL inhibitor in a BLA for IgAN with a July 7, 2026 PDUFA date after Phase 3 ORIGIN 3 met its primary endpoint. The company held $714.6 million in cash as of December 31, 2025 and incurred net losses of $299.6 million in 2025; no product revenue has been generated.